Cargando…

Multinational corporations and infectious disease: Embracing human rights management techniques

BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Salcito, Kendyl, Singer, Burton H, Weiss, Mitchell G, Winkler, Mirko S, Krieger, Gary R, Wielga, Mark, Utzinger, Jürg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323175/
https://www.ncbi.nlm.nih.gov/pubmed/25671119
http://dx.doi.org/10.1186/2049-9957-3-39
_version_ 1782356502629056512
author Salcito, Kendyl
Singer, Burton H
Weiss, Mitchell G
Winkler, Mirko S
Krieger, Gary R
Wielga, Mark
Utzinger, Jürg
author_facet Salcito, Kendyl
Singer, Burton H
Weiss, Mitchell G
Winkler, Mirko S
Krieger, Gary R
Wielga, Mark
Utzinger, Jürg
author_sort Salcito, Kendyl
collection PubMed
description BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseases to thrive, and the diseases, in turn, interact with social-ecological systems to promulgate poverty, inequity and indignity. Governments and intergovernmental organisations should be concerned with the control and elimination of these diseases, as widespread infections delay economic growth and contribute to higher healthcare costs and slower processes for realising universal human rights. These social determinants and economic outcomes associated with infectious diseases should interest multinational companies, partly because they have bearing on corporate productivity and, increasingly, because new global norms impose on companies a responsibility to respect human rights, including the right to health. METHODS: We reviewed historical and recent developments at the interface of infectious diseases, human rights and multinational corporations. Our investigation was supplemented with field-level insights at corporate capital projects that were developed in areas of high endemicity of infectious diseases, which embraced rights-based disease control strategies. RESULTS: Experience and literature provide a longstanding business case and an emerging social responsibility case for corporations to apply a human rights approach to health programmes at global operations. Indeed, in an increasingly globalised and interconnected world, multinational corporations have an interest, and an important role to play, in advancing rights-based control strategies for infectious diseases. CONCLUSIONS: There are new opportunities for governments and international health agencies to enlist corporate business actors in disease control and elimination strategies. Guidance offered by the United Nations in 2011 that is widely embraced by companies, governments and civil society provides a roadmap for engaging business enterprises in rights-based disease management strategies to mitigate disease transmission rates and improve human welfare outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-9957-3-39) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4323175
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43231752015-02-11 Multinational corporations and infectious disease: Embracing human rights management techniques Salcito, Kendyl Singer, Burton H Weiss, Mitchell G Winkler, Mirko S Krieger, Gary R Wielga, Mark Utzinger, Jürg Infect Dis Poverty Research Article BACKGROUND: Global health institutions have called for governments, international organisations and health practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights approach is clear: poverty and inequality create conditions for infectious diseases to thrive, and the diseases, in turn, interact with social-ecological systems to promulgate poverty, inequity and indignity. Governments and intergovernmental organisations should be concerned with the control and elimination of these diseases, as widespread infections delay economic growth and contribute to higher healthcare costs and slower processes for realising universal human rights. These social determinants and economic outcomes associated with infectious diseases should interest multinational companies, partly because they have bearing on corporate productivity and, increasingly, because new global norms impose on companies a responsibility to respect human rights, including the right to health. METHODS: We reviewed historical and recent developments at the interface of infectious diseases, human rights and multinational corporations. Our investigation was supplemented with field-level insights at corporate capital projects that were developed in areas of high endemicity of infectious diseases, which embraced rights-based disease control strategies. RESULTS: Experience and literature provide a longstanding business case and an emerging social responsibility case for corporations to apply a human rights approach to health programmes at global operations. Indeed, in an increasingly globalised and interconnected world, multinational corporations have an interest, and an important role to play, in advancing rights-based control strategies for infectious diseases. CONCLUSIONS: There are new opportunities for governments and international health agencies to enlist corporate business actors in disease control and elimination strategies. Guidance offered by the United Nations in 2011 that is widely embraced by companies, governments and civil society provides a roadmap for engaging business enterprises in rights-based disease management strategies to mitigate disease transmission rates and improve human welfare outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2049-9957-3-39) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-03 /pmc/articles/PMC4323175/ /pubmed/25671119 http://dx.doi.org/10.1186/2049-9957-3-39 Text en © Salcito et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Salcito, Kendyl
Singer, Burton H
Weiss, Mitchell G
Winkler, Mirko S
Krieger, Gary R
Wielga, Mark
Utzinger, Jürg
Multinational corporations and infectious disease: Embracing human rights management techniques
title Multinational corporations and infectious disease: Embracing human rights management techniques
title_full Multinational corporations and infectious disease: Embracing human rights management techniques
title_fullStr Multinational corporations and infectious disease: Embracing human rights management techniques
title_full_unstemmed Multinational corporations and infectious disease: Embracing human rights management techniques
title_short Multinational corporations and infectious disease: Embracing human rights management techniques
title_sort multinational corporations and infectious disease: embracing human rights management techniques
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323175/
https://www.ncbi.nlm.nih.gov/pubmed/25671119
http://dx.doi.org/10.1186/2049-9957-3-39
work_keys_str_mv AT salcitokendyl multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT singerburtonh multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT weissmitchellg multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT winklermirkos multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT kriegergaryr multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT wielgamark multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques
AT utzingerjurg multinationalcorporationsandinfectiousdiseaseembracinghumanrightsmanagementtechniques